# ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

> **NCT00309959** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 37 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Small Cell Carcinoma
- Cervical Squamous Cell Carcinoma
- Recurrent Cervical Carcinoma

## Interventions

- **DRUG:** Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00309959
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2011-02
- **Final completion:** —
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00309959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00309959, "ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00309959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*